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Determination of Fluoxetine and Norfluoxetine 
Concentrations in Cadaveric Allograft Skin 
Brien L. Neudeck, Pharm.D., Thomas E. Taddonio, CTBS, Warren L. Garner, M.D., and 
Lynda S. Welage, Pharm.D. 
Fluoxetine hydrochloride is the sixth most prescribed drug in the United 
States and is administered to treat major depression. A cadaveric skin 
donation was obtained from a 46-year-old woman who died as a result of a 
fluoxetine overdose. Due to the potential penetration of the drug and its 
major metabolite, norfluoxetine, into skin, the safety of using the skin as an 
allograft was questioned. Our evaluation showed that mean concentrations in 
skin were 2304 * 175 and 1353 * 102 ng/g of skin, respectively. The 
skin:plasma ratio was 0.41. Clinically, the amount of fluoxetine that can be 
transferred to an allograft recipient depends on many factors. Based on 
penetration of drug and metabolite into skin, one would have to evaluate 
carefully the risk:benefit ratio of using allografts from a donor who died from 
a fluoxetine overdose. 
(Pharmacotherapy 1998;18(4):851-855) 
Although clinical trials with fluoxetine 
hydrochloride (Prozac; Eli Lilly and Co., 
Indianapolis, IN) have been conducted since 
1976, disposition of the drug and its major 
metabolite, norfluoxetine, have not been fully 
elucidated. Both are lipophilic and have large 
volumes of distribution in humans ( 2 0 4 5  U k g ) ,  
suggesting that they are present in fluids and 
tissues outside the plasma compartment. '  
Limited pharmacokinetic data suggest that they 
are widely distributed in body tissues, with 
highest concentrations in the lungs and liver. 
However, i t  is unknown i f  either drug or 
metabolite distributes into skin. 
From the University of Michigan College of Pharmacy 
(Drs. Neudeck and Welage); University of Michigan Skin 
Bank (Mr. Taddonio and Dr. Garner); and the Section of 
Plastic Surgery (Dr. Garner) and Department of Pharmacy 
(Dr. Welage), University of Michigan Health Systems, Ann 
Arbor. Michigan. 
Cadaveric allograft skin is used to treat second- 
and third-degree burns, abrasions, frostbite, 
infection, ulcers, and autoimmune diseases.2 It is 
usually rejected by the recipient within 7-21 
days, but until rejection, i t  performs many 
functions of healthy skin.  Currently, no 
guidelines prohibit the use of allograft skin from 
donors  who were taking agents' including 
fluoxe tine. 
Knowledge of drug penetration into skin may 
be important when assessing the safety of 
cadaveric skin allografts from patients who die of 
drug overdoses. Unfortunately, there are no data 
regarding penetration of fluoxetine into skin. 
Theoretically, skin allografts obtained from 
patients who die of a fluoxetine overdose could 
contain sufficient quantities of drug and serve as 
a drug reservoir, resulting in  appreciable 
concentrations in the recipient. " 
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and assess the potential correlation between 
concentrations in  the donated skin and in 
supratherapeutic plasma. 
Skin Donation 
Cadaveric skin was obtained from a 46-year- 
old Caucasian woman who died as a result of an 
apparent myocardial infarction. An organ- 
donation agreement was signed by her spouse, 
and the skin was harvested and sent to the skin 
bank for preparation, storage, and eventual 
allografting. According to protocol, the skin was 
kept under quarantine until the final report of 
the autopsy was available. The autopsy revealed 
that the patient had died as a result of a 
fluoxetine overdose, with concentrations of drug 
and metabolite in peripheral blood of 5566 and 
3265 ng/ml, respectively (normal range 47-469 
and 52-446 ng/ml, respectively). No other 
substances were detected. As a precautionary 
measure, due to lack of information regarding the 
penetration of fluoxetine and norfluoxetine into 
skin, the skin was determined to be unfit for use 
as an allograft and was dedicated to research. 
Methods 
The investigation was approved by the 
University of Michigan institutional review board. 
The cadaveric skin measured approximately 2.5 
square feet and was divided into 10 packets, 
control rate frozen, and stored at -75°C for 10 
months before the investigation. Skin from one 
packet was used in the experiment. The packet 
was thawed in a water bath (Cryosan Inc., 
Newton, MA) a t  42°C for 15 minutes and 
opened, and the skin was rinsed with sterile 
saline to wash off glycerin used in the storage 
process. To improve the ability to section each 
sample finely, the skin was meshed with the aid 
of a Bioplasty Mesher (Bioplasty Inc., Minneapolis, 
MN) at a setting of 1: l .  With a scalpel, three 
sections, approximately 1 square inch, were cut 
and their weight recorded. To determine if any 
constituents in the skin interfered with the assay, 
cadaveric skin from a drug-free donor was 
prepared in the same manner. 
Each piece of skin was prepared as follows. 
The skin was finely sectioned into small pieces 
with a scalpel and transferred to a Pyrex 
Tenbroeck tissue grinder (Corning, Corning, 
NY). It was ground for 2 minutes, after which 
methanol 1 ml was added and the material 
ground for an additional 5 minutes.  Two 
additional milliliters of methanol were added to 
the grinder and the entire grinder was placed on 
ice in a sonicator (Fisher Scientific, Pittsburgh, 
PA) for 10 minutes. The skin-methanol mixture 
was drawn off with a borosilicate glass pipette 
and placed into a glass centrifuge tube. The 
process of methanol addition, grinding, and 
sonification was repeated until all skin was 
reduced to fine particles suspended in methanol. 
A total of 7 ml of methanol was used in the 
extraction of each piece of skk .  
The mixture was centrifuged at 5000 rpm for 5 
minutes, and the methanol supernatant drawn off 
and placed in polystyrene tubes. The supernatant 
was then evaporated to approximately 1 ml in a 
nitrogen analytical evaporator (Organomation, 
South Berlin, MA) .  The precise volume of 
supernatant was measured and recorded. 
HPLC Assay 
Fluoxetine and norfluoxetine concentrations in 
the methanol extraction were determined by 
high-performance liquid ' chromatography 
(HPLC) at Warde Laboratories, Ann Arbor, MI. 
The assay methodologies were based on a 
modification of a published method. Briefly, 
deionized water 1 ml, 1 M carbonate buffer (pH 
10) 0.2 ml, protriptyline 1000 ng/ml 0.1 ml, and 
trimipramine 1000 ng/ml 1 ml as internal 
standards were added and mixed with methanol 
extraction 0.5 ml. Hexane 5 ml was then added, 
and each sample was mixed at high speed on a 
tube rotator for 10 minutes and centrifuged for 5 
minutes at 3500 rpm. Of the resulting hexane 
layer, 4.5 ml was transferred to a glass autosampler 
vial and evaporated under nitrogen to dryness at 
35-55OC. The residue was reconstituted with 0.4 
ml of mobile phase and injected into the HPLC 
system, which consisted of a Supelcosil LC-PCN 
5-p column (Supelco, Inc., Bellefonte, PA) and an 
ultraviolet detector at 225 nm. The mobile phase 
consisted of 60: 15:25 (voVvoVvol) acetonitrile, 
methanol, and 0.01 M phosphate buffer. 
Quantification was determined by comparing 
peak height ratios (peak height of drug divided 
by peak height of internal standard) with the 
standard curve. Interday and intraday coefficients 
of variation for both compounds were 5% and 
3%, respectively. The assay was linear along the 
concentrations 25-5000 ng/ml for both 
fluoxetine and norfluoxetine. The minimum 
quantifiable concentration for both was 10 ng/ml. 
1 
Results 
Both fluoxetine and norfluoxetine were 
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Table 1. Amount of Fluoxetine and Norfluoxetine Obtained in Cadaveric Skin 
Amount (ng) Amount/g skin (ng/g) 
Specimen Weight (g) Fluoxetine Norfluoxetine Fluoxetine Norfluoxetine 
1 0.3457 728 427 2106 1235 
2 0.4088 998 573 2441 1402 
3 0.3997 945 568 2364 1421 
Mean i SD 0.384 t 0.034 890 * 143 523 * 82.9 2304 i 175 1353 * 102 
detected in the cadaveric skin (Table 1). Mean 
concentrations were 2304 * 175 and 1353 * 102 
ng/g skin, respectively. The skin:plasma ratio for 
both compounds was 0.41. There were no  
detectable drug concentrations in control skin. 
Discussion 
Both fluoxetine and norfluoxetine were 
detected in the skin of the woman who died from 
fluoxetine overdose. Given the large volume of 
distribution (20-45 f i g )  and extremely high 
plasma concentrations (5566 and 3265 ng/ml 
fluoxetine and norfluoxetine, respectively), this 
was not unexpected. 
These concentrations are less than those 
detected in  other organs after fluoxetine 
overdose.4* In a 28-year-old woman who died of 
an  overdose of the agent,  brain and liver 
fluoxetine concentrations were 3600 and 12800 
ng/g, and norfluoxetine concentrations were 
3200 and 8800 ng/g, respectively. In our  
investigation, mean concentrations in skin were 
2304 and 1353 ng/g, respectively. 
Postmortem plasma concentrations of drug and 
metabolite in the donor are the second highest 
reported in the literature.6 It is possible that they 
were artificially higher than those immediately 
before death, as postmortem redistribution of 
drugs leading to falsely elevated blood concen- 
trations is well documented.’* Due to increased 
pooling of blood and release of drug-rich blood 
from the liver into the larger vessels postmortem, 
drug concentrations obtained at autopsy can be 
considerably higher than those antemortem. 
Digoxin, tricylic antidepressants, and barbiturates 
are more extensively studied, but fluoxetine also 
has this type of redistribution> 
Fluoxetine and norfluoxetine concentrations in 
the skin of this patient were 41% of those in 
peripheral blood. However, if the true antemortem 
plasma concentrations were lower, the 
tissue:plasma ratio would be higher (i.e., > 41%). 
In cases where drugs are known to redistribute 
postmortem, peripheral blood specimens are 
considered to be more reliable. Peripheral blood 
was obtained for the toxicology screen during the 
autopsy of this patient and thus the concentrations 
most likely represent those at the time of death. 
Despite every attempt to detect all fluoxetine 
and norfluoxetine in  the cadaveric skin, the 
possibility remains that the actual concentrations 
are higher than reported. Thus, these amounts 
represent only minimum concentrations for 
several reasons. Specifically, highly bound 
fluoxetine and norfluoxetine may have remained 
in residual skin left over from the extraction 
process. Therefore, the concentrations reflect 
only the amount that was extracted from the 
extracellular fluid after extensive maceration and 
grinding. In addition, variability in the extraction 
method may have prevented additional drug and 
metabolite from being detected. Due to the 
cylindric nature of the tissue grinder, it was 
difficult to retrieve the entire methanol fraction. 
Furthermore, residual methanol containing the 
compounds that saturated the skin pellet after 
centrifugation could not be collected. 
Finally, the concentrations may be only a 
conservative estimate due to uneven dermal 
thickness that is characteristic of cadaveric skin 
allografts. Thickness varies throughout the 
length of each section as a consequence of 
uneven pressure applied to the dermatome when 
skin is harvested. The thickness of samples 
obtained for extraction may not represent that of 
other areas of the allograft. It is conceivable that 
other areas may have been thicker than those we 
sampled and thus may have contained larger 
deposits of drug. However, one could theoretically 
argue that the opposite is true and the average 
thickness may have been less than in our samples. 
Clearly, many factors may have influenced the 
recovery of both compounds. However, as 
indicated, most of them would have led to loss of 
drug recovery, and thus our estimate of total 
amount of drug recovered should be viewed as 
conservative. 
When considering passage of a drug through 
skin into the systemic circulation of healthy 
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describe drug penetration into skin in cases of 
overdose, skin banks are forced to discard the 
skin as unsafe. Ideally, if penetration of drugs 
into skin were known, it might be possible to use 
selected donations for allografting. 
Fluoxetine is prescribed for the treatment of 
major depression, bipolar disorders, obsessive- 
compulsive disorder, obesity, anorexia nervosa, 
bulimia nervosa, and panic attacks.”-” In 1996 
i t  was the sixth most prescribed drug in the 
United States.’* Therefore, it is not surprising 
that it is frequently listed on autopsy reports of 
skin donors. Based our data, it is reasonable to 
expect that the agent and its metabolite distribute 
into skin of patients taking traditional dosages 
with therapeutic concentrations. However, the 
probability of adverse consequences from using 
allografts from such patients is most likely snfall. 
Even if all deposited drug in the allograft were 
transferred to the ,recipient, the quantities would 
be extremely small and possibly below the limit 
of detection. Future studies investigating the 
pharmacokinetics of drug absorption from skin 
allografts will provide valuable information into 
the utility and safety of these products. 
patients, barriers to diffusion must be considered. 
The three primary barriers to drug absorption 
through the skin are the stratum corneum, 
epidermis, and dermis.’ Due to the compositional 
differences of each of these layers, diffusion into 
the systemic circulation depends on a drug’s 
hydrophobicity, so 1 u b i 1 i t  y, and diffusion 
coefficient. In patients requiring skin grafting, 
these layers are often nonexistent or have been 
surgically debrided, and the barrier to diffusion is 
vastly diminished. When a cadaveric allograft 
skin is saturated with drug, combined with the 
fact that blood vessels from the recipient supply 
the skin graft, it is not unreasonable to suspect 
that  drug would cross into the systemic 
circulation. 
Typical skin grafts consist of approximately 
2-3 square feet and weigh 140-210 g (i.e., 20% 
replacement in a 70-kg patient). Based on our 
conservative estimates of the amount  of 
fluoxetine in the skin of this graft, if a patient 
were to receive a 3-square foot, 210-g allograft, 
and assuming all drug deposited in the allograft 
were transferred to the recipient, the cumulative 
dose of fluoxetine received would be 483,840 ng, 
or only 0.484 mg. This small amount is obviously 
not a therapeutic dose. Since the true concentration 
of fluoxetine and norfluoxetine could not be 
determined, it would be prudent to assess the 
risk:benefit ratio of using the allograft. 
Theoretically, even small quantities of drug could 
be transferred and sufficient to cause a hyper- 
sensitivity reaction. 
The number of organ donations has increased 
every year since 1984 due to increased awareness 
of need.1° Skin donations have increased as well, 
yet they do not meet the needs of bum centers 
across the country. Thus, these centers cannot 
afford to reject a donation, and every attempt is 
made to use the skin while maintaining the safety 
of the recipient. These allografts are obtained 
after careful screens of medical records, and 
interviews with medical staff and next of kin for 
medical history and high-risk lifestyles. Samples 
of the donor’s blood are also tested for trans- 
missible diseases such as hepatitis and the human 
immunodeficiency virus. Although agents that 
the donor may have taken while alive are 
documented, they are used as surrogates for 
disease states that would preclude donation 
rather than as excluding variables themselves. 
One would predict that lipophilic drugs with 
large volumes of distribution and the propensity 
to cause toxicities may cause a problem on 
allografting. However, since no published reports 
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